Project Grant HT94252510753
Award Date
8/1/25
Completion Date
7/31/28
Dollars Obligated
$172K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Farmington, CT 06030, USA
Similar Awards
This Project Grant award from the Defense Health Agency, through the Military Medical Research and Development program (CFDA 12.420), provides $514,335 to Yale University to optimize adoptive cellular immunotherapy for rare melanomas. The award began on September 1, 2023 and is scheduled for completion on August 31, 2026. The research aims to transform health care for service members and the American public through innovative and impactful medical solutions, with a focus on developing treatments...
This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,158,989.00 to Yale University to conduct research on optimizing adoptive cellular immunotherapy for rare melanomas. The research project commenced on September 1, 2023 and is scheduled for completion by August 31, 2026. The key objectives of this grant-funded research are to advance innovative medical solutions for rare forms of melanoma that are difficult to...
This federal Project Grant award, with a funding amount of $1,893,376.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant aims to "REVEAL SPATIAL TRANSCRIPTOMIC AND PROTEOMIC SHIFTS IN TUMOR-INFILTRATING IMMUNOCYTES: CHARTING A PATH TO ENHANCED MELANOMA THERAPEUTICS" and will be performed by the Jackson Laboratory, a non-profit biomedical research institution located in Bar Harbor, Maine. The grant's...
The Defense Health Agency has awarded a $657,263 project grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (d.b.a. DFCI) in Boston, MA. The award, effective September 1, 2024 through August 31, 2027, will support DATA-DRIVEN BIOMARKER-INFORMED DECISION ANALYTICS IN MELANOMA: IMPROVING EFFICACY AND REDUCING TOXICITY OF IMMUNE CHECKPOINT BLOCKADE. Through this grant, DFCI will conduct research to develop data-driven...
The U.S. Defense Health Agency awarded a $1,213,276 Project Grant to Yale University under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, effective September 1, 2023 through August 31, 2026, will fund research on the role of vascular mimicry in the outgrowth of dormant melanoma micrometastases. The goal of this research is to transform health care for Service Members and the American public through innovative and impactful medical research on solutions...
The Department of Defense's Defense Health Agency awarded a $558,832 Project Grant to Tufts University School of Medicine under the Military Medical Research and Development program (CFDA 12.420) on September 30, 2024. This grant will support research focused on "Targeting Differentiation Epitope in CD11b of Tumor-Associated Inflammatory Monocytes: A Novel Adjuvant Dendritic Cell Therapy Approach for Mucosal Melanoma." The research aims to develop an innovative dendritic cell-based...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,130,469 to Yale University to uncover the tumor-immune microenvironmental determinants of immunotherapy response in renal cell carcinoma through ex vivo patient-derived models. The research aims to transform health care for Service Members and the American public through innovative and impactful research investigating medical solutions for the battlefield....
The federal Project Grant award of $1,214,375.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is funding a research project led by Yale University. The project is investigating the use of decoy-resistant IL-18 and immune checkpoint inhibitors in preclinical murine and ex vivo patient-derived models of renal cell carcinoma. The award began on September 15, 2024 and is set to conclude on September 14, 2028. The Military Medical Research...
This $646,252 Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420) supports research to uncover cell intrinsic and extrinsic factors governing melanoma dormancy at single-cell resolution. The primary awardee, Trustees of Boston University, will conduct this advanced biomedical research. The University of Virginia will provide academic and technical resources, including experiments generating and validating...
This Project Grant award of $519,854.00 from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports intravital imaging research of melanoma tumors at the University of California Irvine. The goal is to discover mechanisms and improve patient surveillance after checkpoint blockade immunotherapy. The award, with a start date of September 15, 2023 and completion date of September 14, 2026, will fund research to transform healthcare for Service Members...